Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS...
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
About this item
Full title
Author / Creator
Calabresi, Peter A, Dr , Radue, Ernst-Wilhelm, Prof , Goodin, Douglas, MD , Jeffery, Douglas, MD , Rammohan, Kottil W, MD , Reder, Anthony T, MD , Vollmer, Timothy, MD , Agius, Mark A, MD , Kappos, Ludwig, Prof , Stites, Tracy, PhD , Li, Bingbing, PhD , Cappiello, Linda, MD , von Rosenstiel, Philipp, MD and Lublin, Fred D, MD
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. Methods We did this placebo-controlled, double-blind phase 3 study predominantly in the USA (101 of 117 centres). Using a compute...
Alternative Titles
Full title
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1534833682
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1534833682
Other Identifiers
ISSN
1474-4422
E-ISSN
1474-4465
DOI
10.1016/S1474-4422(14)70049-3
